Evidence map›Paper›PMID 29385239›Full record

ArticleJPEN. Journal of parenteral and enteral nutrition2018

Faecalibacterium prausnitzii and a Prebiotic Protect Intestinal Health in a Mouse Model of Antibiotic and Clostridium difficile Exposure.

Sanjoy Roychowdhury, Jennifer Cadnum, Bryan Glueck, Mark Obrenovich, Curtis Donskey, Gail A M Cresci

Abstract read
In one paragraph

Article in JPEN. Journal of parenteral and enteral nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Rational Design of Live Biotherapeutic Products for the Prevention ofbioRxiv : the preprint server for biology · 2024
    Article
  9. Article
  10. Probiotics: insights and new opportunities forCritical reviews in microbiology · 2023
    Review
  11. Gut microbiome and mycobiome in inflammatory bowel disease patients withFrontiers in cellular and infection microbiology · 2023
    Article
  12. Review
  13. Article
  14. Review
  15. Psychoactive Effects ofFrontiers in microbiology · 2022
    Article
  16. Article
  17. Article
  18. Fiber in the ICU: Should it Be a Regular Part of Feeding?Current gastroenterology reports · 2021
    Review
  19. Article
  20. Applications ofFoods (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sanjoy RoychowdhuryLerner Research Institute, Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio, USA.
Jennifer CadnumResearch Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Bryan GlueckLerner Research Institute, Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio, USA.
Mark ObrenovichResearch Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Curtis DonskeyResearch Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Gail A M CresciLerner Research Institute, Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio, USA.
Cleveland Clinic Lerner College of Medicine · USLouis Stokes Cleveland VA Medical Center · USCase Western Reserve University · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024989 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$53.7M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Theresa Torres Pizarro · 2015 to 2026
$15.6M
Targeting ethanol-induced gut dysbiosis with synbiotics to treat alcoholic liverR00AA023266 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI CRESCI, GAIL ANN · 2017 to 2019
$747k
NCATS NIH HHS UL1 TR002548NCRR NIH HHS UL1 RR024989NIAAA NIH HHS R00 AA023266NIDDK NIH HHS P30 DK097948
6 · The paper itself

Abstract

backgroundClostridium difficile (CD) infection (CDI) increases patient morbidity, mortality and healthcare costs. Antibiotic treatment induces gut dysbiosis and is both a major risk factor for CD colonization and treatment of CDI. Probiotics have been trialed to support commensal gut microbiota and reduce CDI. This study investigated commensal microbe Faecalibacterium prausnitzii (FP) and a prebiotic, both known to yield butyrate and be anti-inflammatory and immunomodulatory, on CD colonization and gut integrity in mice.

methodsMice were randomly grouped and supplemented daily with FP, prebiotic, FP + prebiotic, FP/prebiotic supernatant, or saline throughout the entire study. Following treatment with clindamycin for 3 days, mice were exposed to CD. Feces were collected at baseline, the day after antibiotic, and 1, 3, and 5 days after CD exposure and cultured for bacterial overgrowth and CD colonization. On days 1 and 5 after CD exposure, mice were randomly euthanized, and proximal colon was dissected for histological analysis and preparation of RNA for analysis of proinflammatory and anti-inflammatory cytokines.

resultsAlthough all mice exhibited bacterial overgrowth and CD colonization, bacterial burden resolved quicker in the FP + prebiotic group. This was associated with induction and resolution of innate immune responses, anion exchanger, and tight junction protein preservation in proximal colon. CD toxin virulence potential was questionable as expression of CD toxin B receptor was depleted in the FP + prebiotic group.

conclusionSupplementation with anti-inflammatory butyrate-supporting commensal bacteria and prebiotic may support innate immune responses and minimize bacterial burden and negative effects during antibiotic and CD exposure.

Indexed as

Faecalibacterium prausnitziiGastrointestinal MicrobiomePrebioticsAnimalsAnion Transport ProteinsAnti-Bacterial AgentsAnti-Inflammatory AgentsButyratesClindamycinClostridioides difficileClostridium InfectionsColonCytokinesDisease Models, AnimalDysbiosisFecesAnion Transport ProteinsAnti-Bacterial AgentsAnti-Inflammatory AgentsButyratesClindamycinClostridium difficile enterotoxin B receptorCytokinesPrebioticsReceptors, ImmunologicStarchTight Junction Proteinsantibioticsbutyrate, Clostridium difficile, innate immunity, intestine, microbiome, prebiotic, probiotics

Identifiers

PMID29385239
PMCPMC6068000
OpenAlexW2791165755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.